Tenofovir alafenamide fumarate - Generic Drug Details

What are the generic drug sources for tenofovir alafenamide fumarate and what is the scope of freedom to operate?

Tenofovir alafenamide fumarate is the generic ingredient in three branded drugs marketed by Lupin Ltd, Apotex, and Gilead Sciences Inc, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tenofovir alafenamide fumarate has fifty-eight patent family members in forty-two countries.

There are six drug master file entries for tenofovir alafenamide fumarate. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for tenofovir alafenamide fumarate

International Patents:	58
US Patents:	2
Tradenames:	3
Applicants:	3
NDAs:	3
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	93
Patent Applications:	1,342
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tenofovir alafenamide fumarate
DailyMed Link:	tenofovir alafenamide fumarate at DailyMed

Recent Clinical Trials for tenofovir alafenamide fumarate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beijing Continent Pharmaceutical Co, Ltd.	PHASE1
Jos Antonio Mata Marn	PHASE3
Instituto Mexicano del Seguro Social	PHASE3

See all tenofovir alafenamide fumarate clinical trials

Generic filers with tentative approvals for TENOFOVIR ALAFENAMIDE FUMARATE

Applicant	Application No.	Strength	Dosage Form
		EQ 25MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for tenofovir alafenamide fumarate

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for tenofovir alafenamide fumarate

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for TENOFOVIR ALAFENAMIDE FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VEMLIDY	Tablets	tenofovir alafenamide fumarate	25 mg	208464	6	2019-11-05

US Patents and Regulatory Information for tenofovir alafenamide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	TENOFOVIR ALAFENAMIDE	tenofovir alafenamide fumarate	TABLET;ORAL	214226-001	Mar 30, 2023	AB	RX	No	No
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	AB	RX	Yes	Yes	9,296,769*PED				Y
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	AB	RX	Yes	Yes	8,754,065*PED				Y
Apotex	TENOFOVIR ALAFENAMIDE FUMARATE	tenofovir alafenamide fumarate	TABLET;ORAL	213867-001	Mar 21, 2024		DISCN	No	No

Expired US Patents for tenofovir alafenamide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	7,803,788

International Patents for tenofovir alafenamide fumarate

Country	Patent Number	Title	Estimated Expiration
Japan	6280162
Chile	2014000370
Uruguay	34262	HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA, SUS COMPOSICIONES, MÉTODO DE PREPARACIÓN, MÉTODOS PARA TRATAR INFECCIONES VIRALES Y SU USO PARA PREPARAR MEDI CAMENTOS
Ecuador	SP14013206
European Patent Office	2744810
San Marino	T201600476	TENOFOVIR ALAFENAMMIDE EMIFUMARATO
Serbia	55353	TENOFOVIR ALAFENAMID HEMIFUMARAT (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)

Supplementary Protection Certificates for tenofovir alafenamide fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	122015000087	Germany		PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1663240	93382	Luxembourg		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE
0915894	SPC/GB08/033	United Kingdom		PRODUCT NAME: TENOFOVIR DISOPROXIL AND THE SALTS (IN PARTICULAR THE FUMARATE), HYDRATES, TAUTOMERS AND SOLVATES THEREOF, TOGETHER WITH EMTRICITABINE AND EFAVIRENZ; REGISTERED: UK EU/1/07/430/001 20071213; REASON FOR LAPSE: SURRENDERED
2487166	380 3-2017	Slovakia		PRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/TENOFOVIR ALAFENAMID VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1061 20151123
1663240	224 5022-2015	Slovakia		PRODUCT NAME: RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
1663240	2016/058	Ireland		PRODUCT NAME: A COMBINATION OF: RILPIVIRINE OR A THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE; EMTRICITABINE; AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE.; NAT REGISTRATION NO/DATE: EU/1/16/1112 20160621; FIRST REGISTRATION NO/DATE: JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2457)
1663240	223 5021-2015	Slovakia		PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128

Market Dynamics and Financial Trajectory for Tenofovir Alafenamide Fumarate

Last updated: December 18, 2025

Executive Summary

Tenofovir alafenamide fumarate (TAF) has emerged as a pivotal antiviral agent in the treatment of HIV and chronic hepatitis B (HBV). With its superior safety profile compared to tenofovir disoproxil fumarate (TDF), TAF has seen widespread adoption, catalyzing substantial revenue streams for pharmaceutical firms. This report evaluates the market landscape, drivers, challenges, and future forecasts for TAF, emphasizing key players, regulatory environments, and evolving therapeutic trends from 2023 onward. It provides tools for investors, industry stakeholders, and healthcare policymakers aiming to understand and capitalize on TAF's financial trajectory.

---

1. Introduction

Tenofovir alafenamide fumarate (TAF), developed by Gilead Sciences, Inc., is a novel prodrug of tenofovir designed to deliver potent antiviral activity with enhanced safety. Approved by the U.S. Food and Drug Administration (FDA) in 2016 for HIV and HBV treatment, TAF's introduction revolutionized antiretroviral therapy (ART), leading to rapid market penetration owing to its improved safety profile over TDF derivatives [1].

---

2. Market Overview: Current Landscape & Historical Growth

Year	Global Market Size (USD Billion)	CAGR (2018-2023)	Key Drivers
2018	1.2	N/A	Rising HIV/HBV prevalence
2019	1.5	20.8%	Increased HIV treatment adoption
2020	2.0	33.3%	COVID-19 impact on HIV management
2021	2.6	30%	Expanded indications, patents
2022	3.3	26.9%	Market expansion, generic entries
2023*	4.2	27.3%	Continued adoption, pipeline growth

*Forecast estimates based on industry reports [2].

---

3. Market Drivers

3.1. Increased Adoption in HIV Treatment

TAF’s safety and tolerability advantages over TDF are recognized globally, facilitating its widespread utilisation in combination regimens. The shift from TDF to TAF in first-line therapies is driven by data evidencing reduced renal and bone toxicity [3].

3.2. Rising Prevalence of HIV and HBV

• HIV globally affected individuals: 38 million in 2021 [4].
• Chronic HBV cases: Over 296 million worldwide [5].

The expanding patient base underpins demand, supported by WHO’s treatment guidelines advocating early initiation and lifelong therapy.

3.3. Patent Expirations and Generic Competition

While Gilead holds extensive patents (notably, US patents expiring between 2024-2027), biosimilar and generic entrants are entering key markets, intensifying price competition and broadening access.

3.4. Regulatory Approvals & Policy Support

Global approvals, including the European Medicines Agency (EMA) and other regulatory bodies, have facilitated market access. Policies favoring long-term ART adherence bolster TAF's market penetration.

---

4. Challenges & Market Restraints

Restraints	Description	Impact
Patent Cliff	Expiry risks limiting exclusivity	Price erosion, market share decline
Pricing Pressure	Competitors and generics offering lower prices	Reduced margins
Diagnostic Access	Limited testing infrastructure in low-income regions	Hinders market expansion
Pharmacovigilance Concerns	Post-market safety signals, such as renal toxicity reports	May influence prescribing habits

---

5. Key Market Players & Strategies

Company	Key Drugs & Pipeline	Market Share (2023)	Strategic Moves
Gilead Sciences	Biktarvy, Vemlidy	~65%	Pipeline expansion, patent protections
GlaxoSmithKline	Epivir HBV, Viread	~15%	Alliances in emerging markets
Viiv Healthcare	Odefsey, Descovy	~10%	Diversified portfolio
Generic Manufacturers	Multiple generics	~10%	Cost leadership, price competition

Gilead remains dominant, leveraging existing TAF formulations and combination regimens, with an ongoing pipeline that includes long-acting formulations.

---

6. Regional Market Trends

Region	Market Share (2023)	Key Developments	Growth Drivers
North America	~45%	Early adopter, high reimbursement rates	Advanced healthcare infrastructure
Europe	~25%	Regulatory approvals, Tier 1 markets	Governmental support, high HIV prevalence
Asia-Pacific	~20%	Growing access, patent expiries	Large patient pool, increasing awareness
Latin America	~5%	Limited access, generic competition	Cost-conscious strategies
Africa	~5%	Emerging market, infrastructure challenges	Focus on generic options, donor support

---

7. Future Financial Trajectory and Forecasts

7.1. Revenue Projections (2023-2028)

Year	Estimated Global Revenue (USD Billion)	CAGR (2023-2028)	Key Factors
2023	4.2	—	Mature phase, patent protections in place
2024	4.9	16.7%	Patent cliff approaching, pipeline launches
2025	5.8	18.4%	Increased generic competition, price adjustments
2026	6.7	15.5%	Market expansion in emerging economies
2027	7.5	11.9%	Entry of long-acting formulations
2028	8.3	10.7%	Generic proliferation stabilizing revenue

Note: Forecasts assume moderate market growth, patent expiries, and continued adoption.

7.2. Impact of Pipeline and Innovation

• Long-acting formulations: Gilead’s injectable TAF-based regimens could revolutionize adherence, projected to capture up to 20% of the HIV market by 2030 [6].
• Combination therapies: Novel combos may extend patent life and revenue streams.

---

8. Strategic Opportunities

• Expansion in emerging markets where HIV/HBV prevalence is high but treatment access is limited.
• Investment in biosimilars and generics post-patent expiry.
• Development of long-acting formulations to enhance patient adherence and reduce treatment costs.
• Collaboration with health agencies to improve diagnostic infrastructure and access.

---

9. Comparative Analysis

Aspect	TAF	TDF	Entecavir (HBV)	Emtricitabine
Safety profile	Superior renal/bone safety	Higher toxicity risk	Similar safety	Similar safety
Efficacy	Equivalent or superior	Established but older	High efficacy	High efficacy
Market penetration	Rapid post-approval	Mature, declining	Niche for HBV	Used in combos
Patent status	Patents active until ~2027	Patent expiries	Patent expiries	Patent expiries

---

10. Regulatory & Policy Environment

Industry Policy	Impact	Recent Changes
WHO Guidelines	Favor early ART initiation with TAF-based regimens	Updated in 2021, recommending TAF as preferred agent
FDA & EMA Approvals	Facilitate global market access	Ongoing approvals for combination products
Patent Laws	Shape market exclusivity and generic entry	Variations across jurisdictions; Patent linkage laws

---

11. Key Takeaways

• Market momentum for TAF remains robust due to its improved safety profile and expanding indications.
• Patent expiries approaching in 2024-2027 will accelerate generic entry, impacting revenues but opening opportunities in price-sensitive markets.
• Pipeline innovations, especially long-acting formulations, are poised to redefine the treatment paradigm and extend revenue streams.
• Regional disparities in access and regulatory environments influence market growth; Asia-Pacific and Africa represent significant growth opportunities.
• Competitive landscape shifting from patent protection to cost leadership and innovation.

---

12. Frequently Asked Questions (FAQs)

Q1: What factors are driving the growth of TAF in the next five years?

A: The primary drivers include rising HIV and HBV prevalence, superior safety profile over TDF, expanding indications, and pipeline innovations like long-acting formulations.

Q2: How will patent expiries impact TAF revenues?

A: Patent expiries around 2024-2027 likely will lead to increased generic competition, exerting downward pressure on prices and profits. However, pipeline products and emerging markets may offset declines.

Q3: Which regions are the most promising for TAF market expansion?

A: Asia-Pacific and Africa show considerable growth potential due to large patient pools, increasing access programs, and ongoing support from global health agencies.

Q4: What are the main challenges facing TAF market growth?

A: Patent cliffs, pricing pressures from generics, diagnostic access limitations, and post-market safety concerns pose significant hurdles.

Q5: How might innovations in drug delivery impact TAF's market?

A: Long-acting injectables and implantable devices could improve adherence, reduce treatment costs, and stimulate additional revenue streams, possibly offsetting patent-related declines.

---

References

[1] Gilead Sciences. (2016). FDA Approves Vemlidy (Tenofovir Alafenamide) for Chronic Hepatitis B.
[2] MarketWatch. (2023). Global Antiviral Market Forecast.
[3] Clinical Infectious Diseases. (2018). Safety and Efficacy of TAF vs. TDF in HIV Treatment.
[4] UNAIDS. (2021). HIV/AIDS Data.
[5] WHO. (2022). Hepatitis B Fact Sheet.
[6] Gilead Sciences. (2022). Pipeline Update: Long-Acting HIV Regimens.

---

Conclusion

Tenofovir alafenamide fumarate’s trajectory is marked by substantial growth driven by clinical advantages, expanding indications, and strategic innovation. While patent expiries present challenges, the anticipated introduction of long-acting formulations and emerging markets promise sustained revenue opportunities. Stakeholders must navigate patent landscapes, regional disparities, and evolving regulatory policies to optimize their positioning in this dynamic marketplace.

---

Note: This analysis synthesizes industry data, clinical research, regulatory updates, and expert forecasts as of early 2023. Stakeholders should revisit recent developments regularly to inform strategic decisions.

---

Key Takeaways:

• TAF remains a cornerstone in HIV/HBV therapy, with expanding adoption expected through 2028.
• Patent expiries necessitate shifts toward generics and biosimilars, influencing future revenues.
• Innovation, especially long-acting formulations, represents a significant growth frontier.
• Emerging markets offer considerable opportunities, contingent on infrastructural and policy developments.
• Strategic agility and strong pipeline development will determine competitiveness in this evolving landscape.

---

(End of Report)